Yunsong Tong
AbbVie (United States)(US)
Publications by Year
Research Areas
Cancer-related Molecular Pathways, Cancer therapeutics and mechanisms, DNA Repair Mechanisms, Protein Kinase Regulation and GTPase Signaling, Chemical Synthesis and Analysis
Most-Cited Works
- → Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics(2006)129 cited
- → Synthesis and Evaluation of a New Generation of Orally Efficacious Benzimidazole-Based Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors as Anticancer Agents(2009)108 cited
- → A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies(2019)78 cited
- → Conformationally Constrained Substance P Analogues: The Total Synthesis of a Constrained Peptidomimetic for the Phe7-Phe8 Region(2000)71 cited
- → Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: Chemistry, biological activities, and molecular modeling(2008)59 cited
- → Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors(2007)40 cited
- → Constrained Peptidomimetics for TRH: cis-Peptide Bond Analogs(2000)33 cited
- → Design, Synthesis, and Biological Activity of 4-[(4-Cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as Potent and Selective Farnesyltransferase Inhibitors(2004)33 cited
- → Azaindole-Based Inhibitors of Cdc7 Kinase: Impact of the Pre-DFG Residue, Val 195(2013)29 cited
- → Discovery of 4′-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4′-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2′-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors(2007)25 cited